Juan C. Sanabria, an analyst from BMO Capital, reiterated the Buy rating on National Health Investors. The associated price target was raised to $90.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Juan C. Sanabria has given his Buy rating due to a combination of factors that highlight the potential for growth in National Health Investors’ portfolio. The company’s focus on senior housing is expected to continue its above-trend growth, supported by a favorable balance between supply and demand. Additionally, NHI’s ability to engage in accretive acquisitions, backed by a solid weighted average cost of capital, positions it well for external growth opportunities.
Furthermore, the potential upside from National HealthCare Corporation (NHC), which constitutes a significant portion of NHI’s net operating income, could contribute positively to earnings by 2027. The company’s strategy to increase its exposure to SHOP (Senior Housing Operating Portfolio) assets is also noteworthy, with expectations for substantial growth in this area. Despite some concerns about asset management with certain partners, NHI’s strategic initiatives and market positioning provide a strong foundation for future performance.
In another report released on October 1, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock with a $90.00 price target.